DRMAW vs AAPL: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

AAPL has stronger fundamentals based on our AI analysis.

DRMAW
Dermata Therapeutics, Inc.
STRONG SELL
92%
Confidence
VS
AAPL
Apple Inc.
BUY
87%
Confidence

DRMAW vs AAPL Fundamental Comparison

Metric DRMAW AAPL
Revenue $161,357.0 $143.8B
Net Income $-5.7M $42.1B
Net Margin -3,530.5% 29.3%
ROE -143.9% 47.7%
ROA -112.3% 11.1%
Current Ratio 7.66x 0.97x
Debt/Equity 0.00x 1.00x
EPS $-6.64 $2.84

Green = Better metric | Red = Weaker metric

View Full DRMAW Analysis →
View Full AAPL Analysis →

You Might Also Compare

DRMAW vs MSFT AAPL vs GOOGL DRMAW vs AMZN AAPL vs NVDA

DRMAW vs AAPL: Frequently Asked Questions

Is DRMAW or AAPL a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), AAPL has stronger fundamentals. DRMAW is rated STRONG SELL (92% confidence) while AAPL is rated BUY (87% confidence). This is not investment advice.

How does DRMAW compare to AAPL fundamentally?

Dermata Therapeutics, Inc. has ROE of -143.9% vs Apple Inc.'s 47.7%. Net margins are -3,530.5% vs 29.3% respectively.

Which stock pays higher dividends, DRMAW or AAPL?

DRMAW has a dividend yield of N/A or no dividend while AAPL has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in DRMAW or AAPL for long term?

For long-term investing, consider that DRMAW has STRONG SELL rating with 92% confidence, while AAPL has BUY rating with 87% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about DRMAW vs AAPL?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For DRMAW vs AAPL, the AI consensus favors AAPL based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.